Get the Stockscreener App
0.1239
7.47%
-0.010
Pre-market:
.12
-0.0039
-3.15%
AIM ImmunoTech Inc stock is traded at $0.1239, with a volume of 941.44K.
It is down -7.47% in the last 24 hours and down -42.13% over the past month.
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc., Japan National Institute of Infectious Diseases, and Shionogi & Co., Ltd. for the evaluation and discussion of business relationships concerning a COVID-19 therapeutic and vaccine. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
See More
Previous Close:
$0.1339
Open:
$0.135
24h Volume:
941.44K
Relative Volume:
0.97
Market Cap:
$8.52M
Revenue:
$202.00K
Net Income/Loss:
$-28.96M
P/E Ratio:
-0.2065
EPS:
-0.6
Net Cash Flow:
$-21.85M
1W Performance:
-9.56%
1M Performance:
-42.13%
6M Performance:
-66.48%
1Y Performance:
-70.33%
1-Day Range:
$0.1105
$0.135
1-Week Range:
$0.1105
$0.15
52-Week Range:
$0.1105
$0.62
AIM ImmunoTech Inc Stock (AIM) Company Profile
Name
AIM ImmunoTech Inc
Sector
Industry
Phone
352 448 7797
Address
2117 SW Highway 484, Ocala, FL
Compare AIM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AIM
AIM ImmunoTech Inc
|
0.1239 | 8.52M | 202.00K | -28.96M | -21.85M | -0.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
AIM ImmunoTech Inc Stock (AIM) Latest News
AIM ImmunoTech Doses First Subject in Phase 2 of Late-Stage Pancreatic Cancer Study - Marketscreener.com
Hemispherx Biopharma stock hits 52-week low at $0.12 By Investing.com - Investing.com South Africa
Hemispherx Biopharma stock hits 52-week low at $0.12 - Investing.com
AIM ImmunoTech Inc. Announces Dosing of First Subject in Phase 2 Trial of Ampligen Combined with Imfinzi for Late-Stage Pancreatic Cancer - Nasdaq
AIM Doses First New Subject in Phase 2 Study of Ampligen - GlobeNewswire
Can This Dual-Drug Approach Transform Pancreatic Cancer Treatment? AIM Moves Clinical Trial Forward - StockTitan
AIM stock touches 52-week low at $0.13 amid market challenges - MSN
CEO & President Equels Thomas K acquire 20,000 shares of AIM ImmunoTech Inc [AIM] - Knox Daily
AIM ImmunoTech advances Ampligen for avian influenza vaccine - MSN
Hemispherx BioPharma Issues Press Release on Phase 2 Study Collaboration - Defense World
AIM ImmunoTech’s Ampligen Receives Clearance from FDA for Exportation to Argentina for the Treatment of Severe Chronic Fatigue Syndrome - ACCESS Newswire
Hemispherx BioPharma Postpones Offering Pending Annual Report Filing - Defense World
Understanding AIM’s book value per share for better investment insights - US Post News
AIM ImmunoTech Releases Virtual Investor "What This Means Segment” - The Manila Times
AIM ImmunoTech and Erasmus MC Announce Progress on Phase 2 Trial for Ampligen® and Imfinzi® in Late-Stage Pancreatic Cancer - Nasdaq
AIM ImmunoTech Releases Virtual Investor “What This Means Segment” - GlobeNewswire
AIM ImmunoTech announces that it will not proceed with an - GlobeNewswire
AIM ImmunoTech Delays Capital Raise: Key Details on S-1 Offering Postponement - StockTitan
The Potential Rise in the Price of AIM ImmunoTech Inc (AIM) following insiders activity - Knox Daily
AIM's Pancreatic Cancer Trial Milestone: Zero Severe Side Effects, Phase 2 Gets Green Light - StockTitan
AIM ImmunoTech Inc (AIM) Performance and Fundamentals Dashboard tells a completely different story - SETE News
Balance Sheet Dive: AIM ImmunoTech Inc (AIM)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
AIM ImmunoTech announces a planned follow-up clinical study - GlobeNewswire
AIM ImmunoTech announces follow-up clinical study of Ampligen with FluMist - TipRanks
AIM ImmunoTech advances Ampligen for avian influenza vaccine By Investing.com - Investing.com Nigeria
AIM ImmunoTech Inc. Initiates Plan to Advance Ampligen as Vaccine Adjuvant for Avian Influenza - Nasdaq
AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM's Ampligen® and AstraZeneca's FluMist® to address the recent avian influenza outbreaks - The Manila Times
4X Immune Response: AIM's Ampligen Breakthrough with AstraZeneca's FluMist Against Bird Flu - StockTitan
AIM ImmunoTech Inc (AIM) Has Recovered -14.29% From Its Low: Is This The Beginning Of A Trend? - Stocks Register
Stocks of AIM ImmunoTech Inc (AIM) are poised to climb above their peers - SETE News
Erasmus Medical Center Safety Committee Grants Approval to - GlobeNewswire
AIM ImmunoTech Advances Phase 2 DURIPANC Trial Of Ampligen And Imfinzi For Pancreatic Cancer - Nasdaq
AIM ImmunoTech announces Safety Committee approval to proceed with Phase 2 - TipRanks
Investing in AIM ImmunoTech Inc (AIM) might be a great opportunity, but the stock is a bit undervalued - US Post News
Breakthrough in Pancreatic Cancer Treatment: Clinical Trial Shows 15-Month Disease Stability - StockTitan
Daily Progress: AIM ImmunoTech Inc (AIM) Drop -8.07, Closing at 0.19 - The Dwinnex
AIM’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
AIM ImmunoTech (NYSE:AIM) Stock Price Down 8.1% – What’s Next? - Defense World
AIM ImmunoTech Provides Business Update for the Third Quarter of 2019 - ACCESS Newswire
AIM ImmunoTech files to sell units, no amount given - MSN
AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions - Marketscreener.com
AIM ImmunoTech Announces Publication of Final Clinical - GlobeNewswire
AIM ImmunoTech's Ampligen Shows Breakthrough Results in Long COVID Fatigue Treatment Trial - StockTitan
AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS - GlobeNewswire
Are Medical Stocks Lagging Cardinal Health (CAH) This Year? - Yahoo Finance
AIM ImmunoTech's Ampligen Shows Breakthrough Results for Long COVID and ME/CFS Treatment - StockTitan
AIM ImmunoTech (AIM) Upgraded to Strong Buy: What Does It Mean for the Stock? - MSN
Allegion Plc (ALLE-N) QuotePress Release - The Globe and Mail
AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones - GlobeNewswire
AIM ImmunoTech Advances Ampligen Cancer Programs, Reports Strong Clinical Progress Across Pipeline - StockTitan
Mesoblast (NASDAQ:MESO) versus AIM ImmunoTech (NYSE:AIM) Head-To-Head Contrast - Defense World
AIM ImmunoTech Inc Stock (AIM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):